Fachthemen
Abstract
Production in Emerging Growth Markets
Growing demand for local pharmaceutical manufacturing in emerging growth markets is triggered by an aging process of our global population, population growth in asia and africa, strong economic growth in emerging markets and cost pressure on global health care systems. Local manufacturing close to emerging markets offers benefits for market access, subsidies, flexibility, lower per unit costs and positive company reputation. However, disadvantages to be considered might be weak infrastructure, high inflation rates, strong employee turnover rates, coordination efforts for quality and compliance, complexity costs within the supply network. The current pressure to start local manufacturing in many emerging markets needs to be evaluated in light of sustainability and long term profitability. Many local manufacturing projects in the key countries Russia, China, India and Brazil are feasible, whereas in particular in smaller markets the risks may outweigh the benefits and might turn down some investment projects.
![]() | Dr. Barthold Piening studierte Pharmazie an den Universitäten Kiel und Cardiff, promovierte in Kiel in pharmazeutischer Chemie und nahm anschließend die Tätigkeit in der pharmazeutischen Industrie im Jahre 1988 bei der Byk Gulden GmbH auf. Eine MBA-Ausbildung an der WHU Koblenz Vallendar wurde 1999 abgeschlossen. Nach verschiedenen Stationen in der pharmazeutischen Produktion und im Supply Chain Management wurde Dr. Piening 2003 bei der Altana Pharma AG Vice President Operations und 2007 Executive Vice President Operations for die Nycomed GmbH. Seit 2011 leitet Dr. Piening bei der Takeda |